Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 1/2004

01-02-2004 | Original Article

The use of corticosteroid therapy in refractory Kawasaki patients

Author: Sulaiman M. Al-Mayouf

Published in: Clinical Rheumatology | Issue 1/2004

Login to get access

Abstract

We retrospectively reviewed four children with Kawasaki disease refractory to the standard therapy. Although three patients had unusual complications, all four responded to intravenous methylprednisolone. This therapy may be considered early in the treatment of selected cases of Kawasaki disease.
Literature
1.
Wright D, Newburger J, Baker A, Sundel R (1996) Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 128:146–149PubMed
2.
Shinorhara M, Sone K, Tomomasa T, Morikawa A (1999) Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 135:465–469PubMed
3.
Dale R, Saleem M, Daw S, Dillon M (2000) Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr 137:723–726CrossRefPubMed
4.
Rauch A, Hurwitz E (1988) Centers for disease control case definition of Kawasaki syndrome. Pediatr Infect Dis J 142:441–444
5.
Al-Eid W, Jefri A, Bahabri S, Al-Mayouf SM (2000) Haemophagocytosis in complicating Kawasaki disease. J Pediatr Hematol Oncol 17:323–329CrossRef
6.
Terai M, Shulman S (1997) Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 131:888–893PubMed
7.
Newburger J, Takahashi M, Beiser A et al. (1991) A single intravenous infusion of gamma globulin as compared with four in fusions in the treatment in Kawasaki disease. N Engl J Med 324:1633–1639PubMed
8.
Chang J, Lín J, Peng C, Tsai C (1999) Kawasaki disease complicated by peripheral gangrene. Pediatr Cardiol 20:139–142CrossRefPubMed
9.
Sundel R, Burns J Baker A, Beiser A, Newburger J (1993) Gamma globulin re-treatment in Kawasaki disease. J Pediatr 123:657–659PubMed
10.
Burns J, Capparelli E, Brown J, Newburger J, Glode M (1998) Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 17:1144–1148CrossRefPubMed
11.
Kato H, Koike S, Yokoyome T (1979) Kawasaki disease: effect of treatment on coronary involvement. Pediatrics 63:175–179PubMed
12.
Trumble T, Fitch R (1986) Kawasaki disease– A cause of vasculitis in children. J Pediatr Orthop 6:92–95PubMed
13.
Ohga S, Ooshima A, Fukushige J, Ueda K (1995) Histocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state. Eur J Pediatr 154:539–541PubMed
Metadata
Title
The use of corticosteroid therapy in refractory Kawasaki patients
Author
Sulaiman M. Al-Mayouf
Publication date
01-02-2004
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2004
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-003-0752-z

Other articles of this Issue 1/2004

Clinical Rheumatology 1/2004 Go to the issue

Case Report

Destructive joint disease in α-mannosidosis. A case report and review of the literature

Case Report

Two cases of hypertrophic pachymeningitis associated with myeloperoxidase antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive pulmonary silicosis in tunnel workers

Case Report

Inflammatory myopathy in a patient with cutaneous findings of pityriasis rubra pilaris: a case of Wong’s dermatomyositis

Original Article

Is the involvement of the distal interphalangeal joint in psoriatic patients related to nail psoriasis?

Case Report

Keloidal scleroderma

Case Report

CMV enteritis causing ileal perforation in underlying lupus enteritis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits